Phase 2 N=46 A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
Prostate Cancer
Primary: Progression Free Survival — 1.83; 3.7 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=78 Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers
Foot Ulcer, Diabetic · Diabetic Foot
Primary: The Primary Efficacy Parameter Will be the Proportion of Ulcers Healed by 12 Weeks as Defined as 100 % Epithelialized With no Drainage. — 8; 14; 8 number of ulcers healed
Phase 2 N=148 Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea
Irritable Bowel Syndrome With Diarrhea
Primary: The Number of Months That Subjects Are Monthly Responders in Both IBS-related Abdominal Pain AND Stool Consistency During the Entire Three Months. — 18; 27; 28; 9…
Phase 2 N=66 Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
Glioblastoma Multiforme · Gliosarcoma
Primary: Overall Survival — 19 months
Phase 2 N=16 Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Response Rate — 0 percentage of participants
Phase 2 N=105 Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Breast Cancer
Primary: Number of Patients With Pathological Complete Response (pCR) in the Breast and Nodes for Patients With HER2-positive LABC Following Neoadjuvant Treatment (Cohort A) — 34…
Phase 2 N=11 Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Tumor-specific Cytotoxic T-cell Response — 0.496; 0.4836 10^9 cells/L
Phase 2 N=16 Melatonin Supplements for Improving Sleep in Individuals With Hypertension
Sleep Disorders · Hypertension
Primary: Sleep Quality — 88.1; 80.5 % (% asleep during 8 hour opportunity)
Phase 2 N=166 Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study
Non-transfusion Dependent Thalassemia
Primary: Core Study: Change in Liver Iron Concentration (LIC) From Baseline to Week 52 — -1.95; -3.80; 0.38 mg iron (Fe)/g dry weight (dw)
Phase 2 N=27 Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma
Adult T-cell Leukemia-lymphoma
Primary: Overall Response Rate (ORR) — 50 percentage of participants with response
Phase 2 N=307 A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
Carcinoma, Hepatocellular
Primary: Time to Progression (TTP) - Independent Radiological Review (Primary Analysis) — 169; 166 Days — p=0.072
Phase 2 N=7 Lucentis for Inflammatory Macular Edema Trial
Uveitis · Cytoid Macular Edema
Primary: The Mean Change at 3 Months in BSCVA From Baseline — 13 letters
Phase 2 N=166 Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Overall Objective Response Rate (ORR) — 8.1; 10.9 percentage of participants
Phase 2 N=110 Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 18 percentage of participants
Phase 2 N=68 RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
Glioblastoma Multiforme
Primary: Progression-free Survival (PFS) — 11.3 Months